Other
Relapsed AML
0
Pipeline Programs↗
7
Active Trials↗
3
Companies Involved↗
Relapsed AML is an early-stage landscape with 0 programs across 3 companies. The most active players are Marker Therapeutics, Inc., Suzhou Zelgen Biopharmaceuticals Co.,Ltd, Chroma Therapeutics.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
17
clinical trials
Completed6 · 35%
Recruiting4 · 24%
Not yet recruiting2 · 12%
Unknown status2 · 12%
Terminated2 · 12%
Active, not recruiting1 · 6%
Clinical Trials
Trial Activity
17 trials
Imetelstat Combinations in Relapsed AML
Recruiting·—·Phase 1·NCT07320235·36 enrolled
Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT06783790·20 enrolled
Conditioning Regimen Containing Melphalan and Cladribine for Refractory / Relapsed AML
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT06133556·237 enrolled
Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS
Completed·—·Phase 2·NCT00334074·30 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)